P210 Interim results from the RESPOND study evaluating nusinersen in children with spinal muscular atrophy previously treated with onasemnogene abeparvovec
Year: 2023
Type: conference-abstract
Source: Neuromuscular Disorders
Authors: J. Parsons, N. Kuntz, J. Brandsema, C. Proud, R. Finkel, K. Swoboda, R. Masson, R. Foster, Y. Liu, C. Makepeace, S. Singhi, A. Paradis, Z. Berger, S. Rane, K. Somera-Molina
Institutions: Children's Hospital Colorado, Lurie Children's Hospital, Children's Hospital of Philadelphia, Children's Hospital of The King's Daughters, St. Jude Children's Research Hospital, Massachusetts General Hospital, Fondazione IRCCS Istituto Neurologico Carlo Besta, Biogen (United Kingdom), Biogen (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4387310229